Adicet Bio, Inc.

Adicet Bio, Inc.

2.75
USD
-0.03
(-1.08%)
-8.54EPS
66.84MMarket Cap
Mar 17Next Earn

Total Valuation

USD

As of September 30, 2026, Adicet Bio, Inc. carries a market capitalization of 66.84M, placing it among publicly traded companies globally. Its enterprise value stands at -22.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap66.84M
Enterprise Value-22.00M

Important Dates

Adicet Bio, Inc.'s next confirmed earnings release is scheduled for March 17, 2027.

Earnings Date3/17/2027

Share Statistics

As of September 30, 2026, Adicet Bio, Inc. has 9.36M shares outstanding.

Shares Outstanding9.36M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio0.65
P/TBV Ratio0.65
P/FCF Ratio-0.95
P/OCF Ratio-0.95

Financial Position

As of September 30, 2026, Adicet Bio, Inc. maintains a current ratio of 6.09, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.78, indicating elevated leverage, while an interest coverage ratio of -983.70 demonstrates limited ability to service its debt obligations.

Current Ratio6.09
Quick Ratio5.96
Debt / Equity11.78
Debt / EBITDA-0.13
Interest Coverage-983.70

Financial Efficiency

Over the twelve months ended September 30, 2026, Adicet Bio, Inc. posted a negative return on equity (ROE) of -85.91, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -67.55, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 102.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-85.91
Return on Assets (ROA)-67.55
Employee Count102.00

Taxes

USD

Over the twelve months ended September 30, 2026, Adicet Bio, Inc. recorded 144,000.00 in income tax expense. The company reported a pretax loss of -90.85M and -91.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax144,000.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Adicet Bio, Inc.'s stock has declined approximately 74.05% over the past 52 weeks. The 50-day moving average sits at 5.80, while the 200-day moving average is 7.40.

52-Week Price Change-74.05%
50-Day Moving Average5.80
200-Day Moving Average7.40

Income Statement

USD

Over the twelve months ended September 30, 2026, Adicet Bio, Inc. generated - - in revenue and converted that into -91.00M in net income, yielding earnings per share of -8.54. EBITDA reached -90.50M, while operating income came in at -95.55M.

Operating Income-95.55M
Pretax Income-90.85M
Net Income-91.00M
EBITDA-90.50M
EBIT-95.55M
Earnings Per Share (EPS)-8.54

Balance Sheet

USD

As of September 30, 2026, Adicet Bio, Inc. holds 100.95M in cash and equivalents against 12.10M in total debt, resulting in a net debt position of -27.11M. Total book value stands at 102.70M, with working capital of 86.45M providing operational flexibility.

Cash & Cash Equivalents100.95M
Total Debt12.10M
Net Debt-27.11M
Equity (Book Value)102.70M
Book Value Per Share10.97
Working Capital86.45M

Cash Flow

USD

Adicet Bio, Inc. produced -80.14M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -285,000.00 in capital expenditures, free cash flow totaled -80.43M - equivalent to -7.55 per share.

Operating Cash Flow-80.14M
Capital Expenditures-285,000.00
Free Cash Flow-80.43M
FCF Per Share-7.55

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -105.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -112.54, meaning Adicet Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-112.54
FCF Yield-105.76

Stock Splits

Adicet Bio, Inc.'s most recent stock split took place on December 30, 2025 with a 16:1 split ratio.

Last Split Date12/30/2025
Split Ratio16:1

Scores

As of September 30, 2026, Adicet Bio, Inc. has an Altman Z-Score of -7.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-7.44